Janux Therapeutics, Inc. (JANX)
D
Pipeline Grade
Financial Position (from SEC Filings)
$51.8M
Cash & Equivalents
$12.3M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$1,000M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-07-31 | Phase1 Readout | — |
| 2026-10-01 | Phase1 Readout | — |
| 2027-07-01 | Phase1 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07545811 | Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer | PHASE1 | Recruiting | 43 |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | PHASE1 | Active Not Recruiting | 130 |
| NCT05519449 | Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | PHASE1 | Recruiting | 272 |
| NCT07291323 | Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability. | PHASE1 | Recruiting | 60 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.